Analyst Price Target is $2.00
▲ +255.24% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for PainReform in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 255.24% upside from the last price of $0.56.
Current Consensus is
Hold
The current consensus among 1 contributing investment analysts is to hold stock in PainReform. This Hold consensus rating has held steady for over two years.
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Read More